Novanta’s (NASDAQ:NOVT) Q3 2026 sales beat estimates but guides down full-year adjusted EPS
Novanta reported Q3 2026 sales of $305M, beating estimates by 1.3%. Adjusted EPS was $1.05, an 8.6% beat. Adjusted EBITDA was $80.34M, a 4.4% beat. Q4 revenue guidance is $309M, in line with estimates. Full-year adjusted EPS guidance was lowered to $3.69. Operating margin declined to 4.6% from 11.5% YoY, while free cash flow margin increased to 10% from 1.7%.
How this was made
The 30-second read
Why it matters
The guidance reduction is the primary catalyst for potential stock movement.
Market read
First‑report earnings and guidance update for NOVT, providing fresh data for traders.
What to watch
Operating margin compression may be temporary; the 10% free cash flow margin suggests underlying profitability improvement.
Background
Novanta's Q3 2026 earnings beat revenue and EPS expectations, but management trimmed full‑year EPS guidance.
Ticker impact
Novanta reported Q3 2026 results beating revenue and EPS estimates but lowered full-year adjusted EPS guidance to $3.69, indicating a potential earnings downgrade.
likely downside as investors price in lower EPS guidance
EPS guidance fell 0.7% despite a beat on the quarter, which typically triggers sell pressure.
Market effects
Medical device and diagnostic equipment sector may see modest valuation adjustments as peers' guidance trends shift.
U.S. small‑cap healthcare stocks could experience slight pullback.
Limited; impact confined to U.S. listed healthcare niche.
Counterpoint
The EPS guidance cut is modest; the strong revenue beat and improved free cash flow margin could support a rebound if investors focus on cash generation.
Key entities
- CompanyNovanta Inc.
U.S. listed medical device and diagnostic equipment provider.
